English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The polarizing debate about how to control antimicrobialresistant organisms in hospitals continues to focus on methicillin-resistant Staphylococcus aureus (MRSA) and the use of active surveillance cultures. In the United States, MRSA infection causes an estimated 18,650 deaths annually among hospitalized patients [1] and likely cost billions of dollars [2]. The National Nosocomial Infections Surveillance system of the Centers for Disease Control and Prevention reported that, by 2003, >60% of the S. aureus isolates causing nosocomial infections in US hospitals were methicillin resistant [3]. Compared with infections due to methicillin-susceptible strains of 5. aureusy infections due to MRSA are associated with poorer clinical outcomes [4] and increased health care costs [5]. Because the prevalence of MRSA is increasing in hospitals, efforts to control MRSA are gaining more public attention. The control of MRSA in the intensive care

Fact, Fiction, or No Data: What Does Surveillance for Methicillin‐ResistantStaphylococcus aureusPrevent in the Intensive Care Unit?